LANSING — A global drug maker is paying Michigan, 43 other states and the District of Columbia $105 million to settle complaints that the company unlawfully marketed three drugs.
Michigan Attorney General Bill Schuette said this month that Michigan's share of the settlement is $2.6 million.
The settlement resolves allegations that London-based GlaxoSmithKline illegally marketed Advair, Paxil and Wellbutrin for purposes that hadn't been approved by the Food and Drug Administration.
GlaxoSmithKline is prohibited from disseminating information that describes any so-called off-label use.
The asthma drug Advair is the drug maker’s bestselling product. Paxil and Wellbutrin are anti-depressants.